✨ Free AI Report
BioLineRx Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BioLineRx Ltd.
Research Preview

BioLineRx Ltd.: Business Overview, Financials & Competitive Analysis

BioLineRx is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell m...

Analyst-debate audio for BioLineRx Ltd.

AskCyborg analysts argue the bull and bear cases for BioLineRx Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BioLineRx Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Restructured biotech with lean burn, dual clinical programs (pancreatic cancer, glioblastoma), and significant royalty upside...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology & Rare Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest BioLineRx Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BioLineRx Ltd. Overview

Pro stress-test →

BioLineRx is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. The company has transformed into 'BioLineRx 2.0', focusing on lean drug development while retaining solid tumor indication rights for motixafortide.

Strategic Profile

Pro stress-test →

Through major licensing agreements with Ayrmid ($10M upfront + $87M potential milestones) and GloriaBio ($15M upfront + $250M potential milestones), BioLineRx secures non-dilutive capital. The ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer is led by Columbia University and supported by both Regeneron and BioLineRx. BioLineRx also established a joint venture with Hemispherian to develop GLIX1, a Phase 1-ready candidate for glioblastoma, a >$3.7 billion global addressable market.

Competitive Landscape

Pro stress-test →

GLIX1 targets glioblastoma, a >$3.7 billion global market that has seen little innovation since the standard of care was developed in 2005. BioLineRx competes with larger oncology-focused biotech companies and stem cell mobilization developers. Its advantage lies in retained solid tumor rights for motixafortide, lean cost structure, and partnership-based model.

Industry Context

BioLineRx Ltd. operates in Biopharmaceutical - Oncology & Rare Diseases.

Key facts

Founded: 2003 · Headquarters: Hevel Modi'in, Israel · Market cap: $12M (May 2025 estimate)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on BioLineRx Ltd..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BioLineRx Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Stem cell mobilization for hematologic cancersFDA-approved CXCR4 antagonist for stem cell mobilization→DNA damage response inhibitorsCancer immunotherapy and DDR combination approaches→Glioblastoma therapeuticsTumor-targeted immunotherapies for glioblastoma→

Compare BioLineRx Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BioLineRx Ltd. operates in Biopharmaceutical - Oncology & Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology & Rare Diseases research →
NEW · MCP server

Ask your AI assistant about BioLineRx Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BioLineRx Ltd. and its top competitor on Cyborg Score”
“What did BioLineRx Ltd. do this quarter?”
“Is BioLineRx Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does BioLineRx Ltd. do?+
BioLineRx is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell m...
What is BioLineRx Ltd.'s Cyborg Score?+
BioLineRx Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BioLineRx Ltd.'s main competitors?+
Named competitors include Stem cell mobilization for hematologic cancers, DNA damage response inhibitors, Glioblastoma therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full BioLineRx Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BioLineRx Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BioLineRx Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.